Monastrol (Synonyms: (±)-Monastrol)

Name: Monastrol
Brand: MedChemExpress
SKU: HY-101071A
Rating: 5.0 (10 reviews)

Cat. No.: HY-101071A Purity: 99.89%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC₅₀ value of 14 μM.

For research use only. We do not sell to patients.

CAS No. : 329689-23-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Monastrol:

(S)-Monastrol Get quote
Monastrol (Standard) Get quote

10 Publications Citing Use of MCE Monastrol

Cell Imaging/Staining

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Flow Cytometry

: Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049.; Time-lapse images of RPE1 cells stably expressing CENP-A-GFP and Centrin1-GFP (colorful, confocal) for Monastrol (100 μM)-treated cells.

: Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049.; The washout of the Eg5 inhibitor Monastrol reversed the inhibitor-induced spindle shortening into elongation, which triggered kinetochore pivoting towards the main spindle surface.

: Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049.; The experimental correlation of the pivoting angle change and spindle length change for the control (orange), DMSO control (dark green), Monastrol washout (light green), FCPT (blue), Monastrol (purple) and STLC (yellow) treatments along with the theoretical curve calculated based on the experimental parameters from DMSO and STLC experiments.

: Monastrol purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Jan 1;17(2):514-526. [Abstract]; The cell growth curve of NOZ and EH-GB1 exposed to different concentration Monastrol (0, 5, 10, 15, 20 μM) for different lengths of time (0h, 24h, 48h, 72h).

: Monastrol purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Jan 1;17(2):514-526. [Abstract]; Cell cycle distribution after 48 hours of Monastrol treatment (15μM and 20 μM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Kinesin Isoform Specific Products:

View All Isoforms

Kinesin-5/Eg5/KSP Kinesin-6 Kinesin-7/CENP-E Kinesin-12 Kinesin-14 Kinesin-13

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC₅₀ value of 14 μM.

IC₅₀ & Target^[3]

Eg5

14 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human 786-0 cells Growth inhibition of human 786-0 cells	[PMID: 21855351]
A-431	IC₅₀	53 μg/mL Compound: Monastrol	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	[PMID: 21620531]
A549	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 21855351]
A549	IC₅₀	118 μg/mL Compound: Monastrol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21620531]
A549	IC₅₀	> 10 μM Compound: Monastrol	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 21856161]
A549	IC₅₀	> 100 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
ACHN	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 21855351]
AGS	IC₅₀	> 10 μM Compound: Monastrol	Cytotoxicity against human AGS cells after 48 hrs by SRB assay Cytotoxicity against human AGS cells after 48 hrs by SRB assay	[PMID: 21856161]
BXPC-3	EC₅₀	> 100 nM Compound: rac-monastrol	Antiproliferative activity against human BxPC3 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BxPC3 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
C6	IC₅₀	87.83 μM Compound: Manastrol	Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30151081]
C6	IC₅₀	> 200 μM Compound: 1	Antiproliferative activity against rat C6 cells after 24 hrs by MTS assay Antiproliferative activity against rat C6 cells after 24 hrs by MTS assay	[PMID: 30108989]
CAKI-1	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human Caki1 cells Growth inhibition of human Caki1 cells	[PMID: 21855351]
CCRF-CEM	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human CCRF-CEM cells Growth inhibition of human CCRF-CEM cells	[PMID: 21855351]
COLO 205	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human COLO205 cells Growth inhibition of human COLO205 cells	[PMID: 21855351]
COLO 205	IC₅₀	164 μg/mL Compound: Monastrol	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 21620531]
EKVX	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human EKVX cells Growth inhibition of human EKVX cells	[PMID: 21855351]
HCC 2998	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human HCC2998 cells Growth inhibition of human HCC2998 cells	[PMID: 21855351]
HCT-116	EC₅₀	1.2 μM Compound: monastrol	Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy	[PMID: 18793847]
HCT-116	EC₅₀	1.5 μM Compound: monastrol	Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy	[PMID: 18793847]
HCT-116	EC₅₀	24155 nM Compound: rac-monastrol	Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
HCT-116	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human HCT116 cells Growth inhibition of human HCT116 cells	[PMID: 21855351]
HCT-116	IC₅₀	9 μM Compound: 1	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
HCT-116	IC₅₀	> 50 μM Compound: Monastrol	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20934346]
HCT-15	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 21855351]
HL-60(TB)	GI₅₀	25.1 μM Compound: NSC-716782	Growth inhibition of human HL-60(TB) cells Growth inhibition of human HL-60(TB) cells	[PMID: 21855351]
HL-60(TB)	IC₅₀	0.147 μM Compound: Monastrol	Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay	[PMID: 28667871]
HOP-62	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human HOP62 cells Growth inhibition of human HOP62 cells	[PMID: 21855351]
HT-29	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human HT-29 cells Growth inhibition of human HT-29 cells	[PMID: 21855351]
HeLa	IC₅₀	176.9 μM Compound: Monastrol	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29908443]
HeLa	IC₅₀	51.3 μM Compound: 1, monastrol	Induction of monoastral spindles in HeLa cells after 7 hrs Induction of monoastral spindles in HeLa cells after 7 hrs	[PMID: 17587586]
HeLa	IC₅₀	6.1 μM Compound: 1, monastrol	Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs	[PMID: 17587586]
IGROV-1	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human IGROV1 cells Growth inhibition of human IGROV1 cells	[PMID: 21855351]
K562	EC₅₀	> 100 nM Compound: rac-monastrol	Antiproliferative activity against human K562 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human K562 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
K562	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 21855351]
KB 3-1	EC₅₀	56494 nM Compound: rac-monastrol	Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay in presence of zosuquidar Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay in presence of zosuquidar	[PMID: 20597485]
KB 3-1	EC₅₀	85114 nM Compound: rac-monastrol	Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
KB-V1	EC₅₀	45394 nM Compound: rac-monastrol	Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar	[PMID: 20597485]
KB-V1	EC₅₀	99083 nM Compound: rac-monastrol	Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay	[PMID: 20597485]
KM12	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human KM12 cells Growth inhibition of human KM12 cells	[PMID: 21855351]
LOX IMVI	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human LOXIMVI cells Growth inhibition of human LOXIMVI cells	[PMID: 21855351]
M14	GI₅₀	25.1 μM Compound: NSC-716782	Growth inhibition of human M14 cells Growth inhibition of human M14 cells	[PMID: 21855351]
MCF7	IC₅₀	45 μg/mL Compound: Monastrol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21620531]
MCF7	IC₅₀	59.1 μM Compound: Monastrol	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29908443]
MCF7	IC₅₀	73 μM Compound: 1	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
MM1.S	IC₅₀	8.7 μM Compound: 1	Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
MOLT-4	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human MOLT4 cells Growth inhibition of human MOLT4 cells	[PMID: 21855351]
MOLT-4	IC₅₀	0.215 μM Compound: Monastrol	Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay	[PMID: 28667871]
Malme-3M	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human MALME-3M cells Growth inhibition of human MALME-3M cells	[PMID: 21855351]
NCI-H1299	EC₅₀	> 100 nM Compound: rac-monastrol	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
NCI-H226	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human NCI-H226 cells Growth inhibition of human NCI-H226 cells	[PMID: 21855351]
NCI-H23	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 21855351]
NCI-H322M	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human NCI-H322M cells Growth inhibition of human NCI-H322M cells	[PMID: 21855351]
NCI-H522	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human NCI-H522 cells Growth inhibition of human NCI-H522 cells	[PMID: 21855351]
OVCAR-3	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR3 cells Growth inhibition of human OVCAR3 cells	[PMID: 21855351]
OVCAR-4	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR4 cells Growth inhibition of human OVCAR4 cells	[PMID: 21855351]
OVCAR-5	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human OVCAR5 cells Growth inhibition of human OVCAR5 cells	[PMID: 21855351]
OVCAR-8	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR8 cells Growth inhibition of human OVCAR8 cells	[PMID: 21855351]
SF-268	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human SF268 cells Growth inhibition of human SF268 cells	[PMID: 21855351]
SF-295	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SF295 cells Growth inhibition of human SF295 cells	[PMID: 21855351]
SF-539	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human SF539 cells Growth inhibition of human SF539 cells	[PMID: 21855351]
SK-MEL-2	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-2 cells Growth inhibition of human SK-MEL-2 cells	[PMID: 21855351]
SK-MEL-28	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-28 cells Growth inhibition of human SK-MEL-28 cells	[PMID: 21855351]
SK-MEL-5	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-5 cells Growth inhibition of human SK-MEL-5 cells	[PMID: 21855351]
SK-OV-3	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human SKOV3 cells Growth inhibition of human SKOV3 cells	[PMID: 21855351]
SN12C	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SN12C cells Growth inhibition of human SN12C cells	[PMID: 21855351]
SNB-19	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human SNB19 cells Growth inhibition of human SNB19 cells	[PMID: 21855351]
SNB-75	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SNB75 cells Growth inhibition of human SNB75 cells	[PMID: 21855351]
SR	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SR cells Growth inhibition of human SR cells	[PMID: 21855351]
SW-620	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 21855351]
TK-10	GI₅₀	100 μM Compound: NSC-716782	Growth inhibition of human TK10 cells Growth inhibition of human TK10 cells	[PMID: 21855351]
U-251	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human U251 cells Growth inhibition of human U251 cells	[PMID: 21855351]
U138-MG	IC₅₀	> 200 μM Compound: 1	Antiproliferative activity against human U138MG cells after 24 hrs by MTS assay Antiproliferative activity against human U138MG cells after 24 hrs by MTS assay	[PMID: 30108989]
UACC-257	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human UACC257 cells Growth inhibition of human UACC257 cells	[PMID: 21855351]
UACC-62	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human UACC62 cells Growth inhibition of human UACC62 cells	[PMID: 21855351]
UO-31	GI₅₀	100 μM Compound: NSC-716782	Growth inhibition of human UO31 cells Growth inhibition of human UO31 cells	[PMID: 21855351]

In Vitro

Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. Monastrol treatment of dividing cells results in spindle collapse and cell cycle arrest with a monoastral spindle, which is similar to the phenotype observed when Eg5 is inhibited by anti-Eg5 antibodies^[1]. Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. Monastrol treatment can decrease cell viability in MCF-7 tumor cells. Real-time cell growth kinetic analysis showed a decrease in the proliferation of MCF-7 cells exposed to monastrol^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

292.35

Formula

C₁₄H₁₆N₂O₃S

CAS No.

329689-23-8

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=C(C)NC(NC1C2=CC=CC(O)=C2)=S)OCC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (342.06 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4206 mL	17.1028 mL	34.2056 mL
5 mM	0.6841 mL	3.4206 mL	6.8411 mL
10 mM	0.3421 mL	1.7103 mL	3.4206 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.89%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (251 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67. [Content Brief]

[2]. Mayer TU, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999 Oct 29;286(5441):971-4. [Content Brief]

[3]. Marques LA, et al. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1279-1288. [Content Brief]

Cell Assay
^[2]

The cytotoxicity assay is performed with MTT. Cells are seeded in 96-well culture plates (5000 cells/well) and incubated for 24 h for stabilization. After this period, the following treatments are administered for 24 and 48 h: vehicle control (0.5 % DMSO); 1 μM doxorubicin and monastrol at 5, 25, 50, 75, and 100 μM. After each time of treatment, the medium is withdrawn, serum-free media containing 0.5 mg/mL MTT salt is added and incubated for 4 h, and formazan crystal products are diluted^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67. [Content Brief]

[2]. Mayer TU, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999 Oct 29;286(5441):971-4. [Content Brief]

[3]. Marques LA, et al. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1279-1288. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4206 mL	17.1028 mL	34.2056 mL	85.5139 mL
	5 mM	0.6841 mL	3.4206 mL	6.8411 mL	17.1028 mL
	10 mM	0.3421 mL	1.7103 mL	3.4206 mL	8.5514 mL
	15 mM	0.2280 mL	1.1402 mL	2.2804 mL	5.7009 mL
	20 mM	0.1710 mL	0.8551 mL	1.7103 mL	4.2757 mL
	25 mM	0.1368 mL	0.6841 mL	1.3682 mL	3.4206 mL
	30 mM	0.1140 mL	0.5701 mL	1.1402 mL	2.8505 mL
	40 mM	0.0855 mL	0.4276 mL	0.8551 mL	2.1378 mL
	50 mM	0.0684 mL	0.3421 mL	0.6841 mL	1.7103 mL
	60 mM	0.0570 mL	0.2850 mL	0.5701 mL	1.4252 mL
	80 mM	0.0428 mL	0.2138 mL	0.4276 mL	1.0689 mL
	100 mM	0.0342 mL	0.1710 mL	0.3421 mL	0.8551 mL

Monastrol Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Monastrol329689-23-8(±)-MonastrolKinesinApoptosisInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Monastrol (Synonyms: (±)-Monastrol)

Customer Review

Other Forms of Monastrol:

Monastrol Related Antibodies

10 Publications Citing Use of MCE Monastrol

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Kinesin Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Monastrol Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Monastrol Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report